Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
In vivo evolution of drug resistance in Cryptococcus
FY 2014-15
Summary
Fungal pathogens affect billions of people each year. These pathogens are particularly harmful to individuals affected by HIV/AIDS, those who have received organ transplants, or are undergoing immunosuppressive therapy. Infection from Cryptococcus neoformans is estimated to affect 1 million people annually and is the leading cause of fungal mortality. Cryptococcosis has extremely high mortality rates, typically around 20-40% in developed countries, and even higher in under-developed countries. Importantly, fungal infections can also affect immunocompentent people, highlighted by a recent outbreak of C. gattii, a very closely-related species, among otherwise healthy people in North America. Fungal infections are notoriously difficult to treat, as fungal cells are very similar to human cells and drug development is difficult. Recent work has shown that polyploid titan cells (i.e., cells that contain more than one set of chromosomes) are critical for the establishment and progression of C. neoformans infection, and that drug resistance can be achieved through aneuploidy (an uneven number of chromosomes). In my proposed work I will use mice to compare populations of fungal cells in different locations in the body as infection progresses and over multiple infection cycles. I will measure variation in disease-related traits including drug resistance, presence of titan cells, and degree of aneuploidy. Experiments will be done with both C. neoformans and C. gattii, and in the presence and absence of drug. Variation in cryptococcal populations during infection has not been previously characterized in this manner. My research will improve understanding of how cryptococcal species are able to evolve in response to the host environment. Ultimately, if we are to develop better treatment strategies to improve patient survival, we must understand the degree of variability of the cryptococcal populations and how this variance promotes survival and disease in the host.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Minnesota, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
315706
Name
Gerstein Aleeza
Region
Minnesota
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
In vivo evolution of drug resistance in Cryptococcus
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Adaptation; Aneuploidy; Cryptoccocus; Drug Resistance; Genomics; Genotypic Variation; Medical Mycology; Murine Model; Phenotypic Variation; Ploidy
Abstract
Fungal pathogens affect billions of people each year. These pathogens are particularly harmful to individuals affected by HIV/AIDS, those who have received organ transplants, or are undergoing immunosuppressive therapy. Infection from Cryptococcus neoformans is estimated to affect 1 million people annually and is the leading cause of fungal mortality. Cryptococcosis has extremely high mortality rates, typically around 20-40% in developed countries, and even higher in under-developed countries. Importantly, fungal infections can also affect immunocompentent people, highlighted by a recent outbreak of C. gattii, a very closely-related species, among otherwise healthy people in North America. Fungal infections are notoriously difficult to treat, as fungal cells are very similar to human cells and drug development is difficult. Recent work has shown that polyploid titan cells (i.e., cells that contain more than one set of chromosomes) are critical for the establishment and progression of C. neoformans infection, and that drug resistance can be achieved through aneuploidy (an uneven number of chromosomes). In my proposed work I will use mice to compare populations of fungal cells in different locations in the body as infection progresses and over multiple infection cycles. I will measure variation in disease-related traits including drug resistance, presence of titan cells, and degree of aneuploidy. Experiments will be done with both C. neoformans and C. gattii, and in the presence and absence of drug. Variation in cryptococcal populations during infection has not been previously characterized in this manner. My research will improve understanding of how cryptococcal species are able to evolve in response to the host environment. Ultimately, if we are to develop better treatment strategies to improve patient survival, we must understand the degree of variability of the cryptococcal populations and how this variance promotes survival and disease in the host.
Competitiondate
201409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gerstein, Aleeza
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~